Research Professor Gary Ostroff
Research Professor Ostroff earned his Ph.D. at the University of Delaware and did a postdoctoral fellowship at UMass Medical School. Before joining UMMS, he taught at Worcester Polytechnic Institute and served in research positions for Genzyme Corporation, Alpha-Beta Technology, Biothera Pharmaceuticals, and Amerifit Nutrition. He founded GlucaDel, Inc to commercialize oral and systemic payload delivery properties of yeast beta glucan particles. His research focuses on glycan-based nanoparticles for delivery of biological materials, the development of carbohydrate and protein therapeutics, diagnostics, target discovery, assay development and small molecule drug screening from Discovery through Phase III clinical studies. His recent accomplishments include the development of the Glucan Particle drug, protein, nucleic acid, small molecule and nanoparticle delivery technologies. He has worked on over 20 federal, state, and private grants utilizing the Glucan Particle drug delivery technology to deliver DNA/siRNA/miRNA/antisense oligonucleotides, protein/peptides, small molecules, and nanoparticles for a wide range of therapeutic applications.